Nadeau G, Ouimet-Grennan E, Aaron M, Drouin S, Bertout L, Shalmiev A, Beaulieu P, St-Onge P, Veilleux LN, Rauch F, Petrykey K, Laverdière C, Sinnett D, Alos N, Krajinovic M

Pharmacogenomics and Personalized Medicine 2019, 12:33-45

Published Date: 11 April 2019

Original Research

Population’s perspectives toward biobanks in scientific research: a study from Jordan

Makhlouf H, Alrabadi N, Khabour OF, Alzoubi KH, Al-Delaimy W

Pharmacogenomics and Personalized Medicine 2019, 12:23-32

Published Date: 21 March 2019

Original Research

Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease

AL-Eitan LN, Almasri AY, Al-Habahbeh SO

Pharmacogenomics and Personalized Medicine 2019, 12:15-22

Published Date: 21 March 2019

Review

Precision medicine approaches for the management of Ewing sarcoma: current perspectives

Rizk VT, Walko CM, Brohl AS

Pharmacogenomics and Personalized Medicine 2019, 12:9-14

Published Date: 17 January 2019

Original Research

Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy

AL-Eitan LN, Almasri AY, Al-Habahbeh SO

Pharmacogenomics and Personalized Medicine 2019, 12:1-8

Published Date: 14 January 2019

Review

Precision pharmacotherapy: psychiatry’s future direction in preventing, diagnosing, and treating mental disorders

Menke A

Pharmacogenomics and Personalized Medicine 2018, 11:211-222

Published Date: 19 November 2018

Original Research

Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study

Baghdadi LR, Woodman RJ, Shanahan EM, Wiese MD, Mangoni AA

Pharmacogenomics and Personalized Medicine 2018, 11:205-210

Published Date: 12 November 2018

Original Research

Influence of MSI and 18q LOH markers on capecitabine adjuvant monotherapy in colon cancer patients

Matevska-Geshkovska N, Staninova-Stojovska M, Kapedanovska-Nestorovska A, Petrushevska-Angelovska N, Panovski M, Grozdanovska B, Mitreski N, Dimovski A

Pharmacogenomics and Personalized Medicine 2018, 11:193-203

Published Date: 1 November 2018

Original Research

CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort

Dagostino C, Allegri M, Napolioni V, D'Agnelli S, Bignami E, Mutti A, van Schaik RHN

Pharmacogenomics and Personalized Medicine 2018, 11:179-191

Published Date: 24 October 2018

Original Research

Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients

Galvez JM, Restrepo CM, Contreras NC, Alvarado C, Calderón-Ospina CA, Peña N, Cifuentes RA, Duarte D, Laissue P, Fonseca DJ

Pharmacogenomics and Personalized Medicine 2018, 11:169-178

Published Date: 16 October 2018

Corrigendum

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty [Corrigendum]

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:167-168

Published Date: 26 September 2018

Original Research

Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension

Sychev D, Shikh N, Morozova T, Grishina E, Ryzhikova K, Malova E

Pharmacogenomics and Personalized Medicine 2018, 11:157-165

Published Date: 20 September 2018

Review

ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients

Uruga H, Mino-Kenudson M

Pharmacogenomics and Personalized Medicine 2018, 11:147-155

Published Date: 17 September 2018

Original Research

Qualitative user evaluation of a revised pharmacogenetic educational toolkit

Mills R, Haga SB

Pharmacogenomics and Personalized Medicine 2018, 11:139-146

Published Date: 4 September 2018

Original Research

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:127-137

Published Date: 25 July 2018

Original Research

The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders

Levchenko A, Losenkov IS, Vyalova NM, Simutkin GG, Bokhan NA, Wilffert B, Loonen AJM, Ivanova SA

Pharmacogenomics and Personalized Medicine 2018, 11:121-126

Published Date: 20 July 2018

Original Research

Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder

Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2018, 11:113-119

Published Date: 29 June 2018

Original Research

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole

Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA

Pharmacogenomics and Personalized Medicine 2018, 11:107-112

Published Date: 18 June 2018

Original Research

Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population

Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J

Pharmacogenomics and Personalized Medicine 2018, 11:95-106

Published Date: 8 June 2018

Review

Emerging biomarkers in the diagnosis of prostate cancer

Filella X, Fernández-Galan E, Fernández Bonifacio R, Foj L

Pharmacogenomics and Personalized Medicine 2018, 11:83-94

Published Date: 16 May 2018

Original Research

Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation

Asleh R, Briasoulis A, Berinstein EM, Wiener JB, Palla M, Kushwaha SS, Levy AP

Pharmacogenomics and Personalized Medicine 2018, 11:71-82

Published Date: 23 April 2018

Short Report

Budget impact model for oncopharmacogenetics from the perspective of mandatory basic health insurance in Switzerland using the example of breast cancer

Szucs TD, Szillat KP, Blozik E

Pharmacogenomics and Personalized Medicine 2018, 11:67-69

Published Date: 23 April 2018

Review

H3Africa: current perspectives

Mulder N, Abimiku A, Adebamowo SN, de Vries J, Matimba A, Olowoyo P, Ramsay M, Skelton M, Stein DJ

Pharmacogenomics and Personalized Medicine 2018, 11:59-66

Published Date: 10 April 2018

Review

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment

Silvado CE, Terra VC, Twardowschy CA

Pharmacogenomics and Personalized Medicine 2018, 11:51-58

Published Date: 29 March 2018

Original Research

Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke

Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO

Pharmacogenomics and Personalized Medicine 2018, 11:43-49

Published Date: 22 March 2018

Original Research

The utility of pharmacogenetic testing to support the treatment of bipolar disorder

Ielmini M, Poloni N, Caselli I, Espadaler J, Tuson M, Grecchi A, Callegari C

Pharmacogenomics and Personalized Medicine 2018, 11:35-42

Published Date: 16 March 2018

Review

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment

Chen L, Prasad GV

Pharmacogenomics and Personalized Medicine 2018, 11:23-33

Published Date: 7 March 2018

Original Research

Which attributes of whole genome sequencing tests are most important to the general population? Results from a German preference study

Plöthner M, Schmidt K, Schips C, Damm K

Pharmacogenomics and Personalized Medicine 2018, 11:7-21

Published Date: 14 February 2018

Original Research

The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction

Zastrozhin MS, Grishina EA, Ryzhikova KA, Smirnov VV, Savchenko LM, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2018, 11:1-5

Published Date: 28 December 2017

Original Research

Ethiopian health care professionals’ knowledge, attitude, and interests toward pharmacogenomics

Abdela OA, Bhagavathula AS, Gebreyohannes EA, Tegegn HG

Pharmacogenomics and Personalized Medicine 2017, 10:279-285

Published Date: 5 December 2017

Review

Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran

Rizk M, Tüzmen S

Pharmacogenomics and Personalized Medicine 2017, 10:267-278

Published Date: 10 November 2017

Review

Pharmacogenomics of sickle cell disease: steps toward personalized medicine

Husain M, Hartman AD, Desai P

Pharmacogenomics and Personalized Medicine 2017, 10:261-265

Published Date: 19 October 2017

Original Research

Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients

Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA

Pharmacogenomics and Personalized Medicine 2017, 10:253-259

Published Date: 27 September 2017

Perspectives

Pharmacogenomic testing: aiding in the management of psychotropic therapy for adolescents with autism spectrum disorders

Bose-Brill S, Xing J, Barnette DJ, Hanks C

Pharmacogenomics and Personalized Medicine 2017, 10:247-252

Published Date: 25 September 2017

Original Research

Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?

Rytkin E, Mirzaev KB, Grishina EA, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Giliarov MI, Andreev DA, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:243-245

Published Date: 18 September 2017

Original Research

ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine

Piatkov I, Caetano D, Assur Y, Lau SL, Jones T, Boyages SC, McLean M

Pharmacogenomics and Personalized Medicine 2017, 10:235-242

Published Date: 28 August 2017

Letter

Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele

Naidoo A, Naidoo K, Ramsuran V, Reddy M, Padayatchi N

Pharmacogenomics and Personalized Medicine 2017, 10:233-234

Published Date: 23 August 2017

Review

Updating the landscape of direct-to-consumer pharmacogenomic testing

Filipski KK, Murphy JD, Helzlsouer KJ

Pharmacogenomics and Personalized Medicine 2017, 10:229-232

Published Date: 22 August 2017

Original Research

CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications

St Sauver JL, Olson JE, Roger VL, Nicholson WT, Black III JL, Takahashi PY, Caraballo PJ, Bell EJ, Jacobson DJ, Larson NB, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:217-227

Published Date: 24 July 2017

Original Research

Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder

Zastrozhin MS, Brodyansky VM, Skryabin VY, Grishina EA, Ivashchenko DV, Ryzhikova KA, Savchenko LM, Kibitov AO, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:209-215

Published Date: 7 July 2017

Review

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele

Panagopoulos P, Maltezos E, Hatzakis A, Paraskevis D

Pharmacogenomics and Personalized Medicine 2017, 10:205-208

Published Date: 20 June 2017

Review

Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies

Yamamoto-Furusho JK

Pharmacogenomics and Personalized Medicine 2017, 10:197-204

Published Date: 26 May 2017

Original Research

Observational study to calculate addictive risk to opioids: a validation study of a predictive algorithm to evaluate opioid use disorder

Brenton A, Richeimer S, Sharma M, Lee C, Kantorovich S, Blanchard J, Meshkin B

Pharmacogenomics and Personalized Medicine 2017, 10:187-195

Published Date: 18 May 2017

Short Report

CYP2C19*2 status in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis

Laska AJ, Han MJ, Lospinoso JA, Brown PJ, Beachkofsky TM

Pharmacogenomics and Personalized Medicine 2017, 10:183-186

Published Date: 17 May 2017

Review

ABCB1 genetic variants in leukemias: current insights into treatment outcomes

Ankathil R

Pharmacogenomics and Personalized Medicine 2017, 10:169-181

Published Date: 12 May 2017

Original Research

DNA methylation at the mu-1 opioid receptor gene (OPRM1) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion

Chidambaran V, Zhang X, Martin LJ, Ding L, Weirauch MT, Geisler K, Stubbeman BL, Sadhasivam S, Ji H

Pharmacogenomics and Personalized Medicine 2017, 10:157-168

Published Date: 9 May 2017

Review

Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response

Abaji R, Krajinovic M

Pharmacogenomics and Personalized Medicine 2017, 10:143-156

Published Date: 5 May 2017

Review

ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches

Cleophas MC, Joosten LA, Stamp LK, Dalbeth N, Woodward OM, Merriman TR

Pharmacogenomics and Personalized Medicine 2017, 10:129-142

Published Date: 20 April 2017

Methodology

Pharmacogenetic testing revisited: 5′nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19

Larsen JB, Rasmussen JB

Pharmacogenomics and Personalized Medicine 2017, 10:115-128

Published Date: 18 April 2017

Original Research

CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome

Mirzaev KB, Zelenskaya EM, Barbarash OL, Ganyukov VI, Apartsin KA, Saraeva NO, Nikolaev KY, Ryzhikova KA, Lifshits GI, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:107-114

Published Date: 12 April 2017

Original Research

Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients

Salgado PC, Genvigir FDV, Felipe CR, Tedesco-Silva Jr H, Medina-Pestana JO, Doi SQ, Hirata MH, Hirata RDC

Pharmacogenomics and Personalized Medicine 2017, 10:101-106

Published Date: 31 March 2017

Original Research

Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations

Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA, Snalina NE, Sozaeva ZA, Grabuzdov AM, Matsneva IA

Pharmacogenomics and Personalized Medicine 2017, 10:93-99

Published Date: 31 March 2017

Review

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals

Trinks J, Caputo M, Hulaniuk ML, Corach D, Flichman D

Pharmacogenomics and Personalized Medicine 2017, 10:79-91

Published Date: 28 March 2017

Review

MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy

Umerez M, Gutierrez-Camino Á, Muñoz-Maldonado C, Martin-Guerrero I, Garcia-Orad A

Pharmacogenomics and Personalized Medicine 2017, 10:69-78

Published Date: 27 March 2017

Review

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment

Takano M, Sugiyama T

Pharmacogenomics and Personalized Medicine 2017, 10:61-68

Published Date: 28 February 2017

Review

Is there evidence that we should screen the general population for Lynch syndrome with genetic testing? A systematic review

Prince AER, Cadigan RJ, Henderson GE, Evans JP, Adams M, Coker-Schwimmer E, Penn DC, Van Riper M, Corbie-Smith G, Jonas DE

Pharmacogenomics and Personalized Medicine 2017, 10:49-60

Published Date: 20 February 2017

Original Research

Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6

Takahashi PY, Ryu E, Pathak J, Jenkins GD, Batzler A, Hathcock MA, Black JL, Olson JE, Cerhan JR, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:39-47

Published Date: 14 February 2017

Review

The HLA-A*31:01 allele: influence on carbamazepine treatment

Yip VLM, Pirmohamed M

Pharmacogenomics and Personalized Medicine 2017, 10:29-38

Published Date: 31 January 2017

Original Research

Prevalence of clinically actionable genotypes and medication exposure of older adults in the community

Daneshi N, Holliday E, Hancock S, Schneider JJ, Scott RJ, Attia J, Milward EA

Pharmacogenomics and Personalized Medicine 2017, 10:17-27

Published Date: 27 January 2017

Original Research

Diet and lifestyle factors associated with miRNA expression in colorectal tissue

Slattery ML, Herrick JS, Mullany LE, Stevens JR, Wolff RK

Pharmacogenomics and Personalized Medicine 2017, 10:1-16

Published Date: 20 December 2016

Review

CYP2D6 polymorphisms and their influence on risperidone treatment

Puangpetch A, Vanwong N, Nuntamool N, Hongkaew Y, Chamnanphon M, Sukasem C

Pharmacogenomics and Personalized Medicine 2016, 9:131-147

Published Date: 1 December 2016

Review

Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics

Lally J, Gaughran F, Timms P, Curran SR

Pharmacogenomics and Personalized Medicine 2016, 9:117-129

Published Date: 7 November 2016

Original Research

Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study

Finkelstein J, Friedman C, Hripcsak G, Cabrera M

Pharmacogenomics and Personalized Medicine 2016, 9:107-116

Published Date: 14 October 2016

Review

Pharmacogenomics of statins: understanding susceptibility to adverse effects

Kitzmiller JP, Mikulik EB, Dauki AM, Mukherjee C, Luzum JA

Pharmacogenomics and Personalized Medicine 2016, 9:97-106

Published Date: 3 October 2016

Original Research

The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction

Sychev DA, Zastrozhin MS, Smirnov VV, Grishina EA, Savchenko LM, Bryun EA

Pharmacogenomics and Personalized Medicine 2016, 9:89-95

Published Date: 14 September 2016

Letter

Comments on Lucire and Crotty, 2011

Loonen AJM, Verkes RJ

Pharmacogenomics and Personalized Medicine 2016, 9:85-87

Published Date: 18 August 2016

Case Series

Use of combinatorial pharmacogenomic testing in two cases from community psychiatry

Fields ES, Lorenz RA, Winner JG

Pharmacogenomics and Personalized Medicine 2016, 9:79-84

Published Date: 16 August 2016

Review

Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives

Patel JN

Pharmacogenomics and Personalized Medicine 2016, 9:65-77

Published Date: 12 July 2016

Short Report

The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia

Sychev DA, Shuev GN, Chertovskih JV, Maksimova NR, Grachev AV, Syrkova OA

Pharmacogenomics and Personalized Medicine 2016, 9:59-63

Published Date: 25 May 2016

Review

The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment

Tulsyan S, Mittal RD, Mittal B

Pharmacogenomics and Personalized Medicine 2016, 9:47-58

Published Date: 27 April 2016

Case Series

Potential utility of precision medicine for older adults with polypharmacy: a case series study

Finkelstein J, Friedman C, Hripcsak G, Cabrera M

Pharmacogenomics and Personalized Medicine 2016, 9:31-45

Published Date: 15 April 2016

Review

Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents

Dawed AY, Zhou K, Pearson ER

Pharmacogenomics and Personalized Medicine 2016, 9:17-29

Published Date: 6 April 2016

Review

Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives

Myers MB

Pharmacogenomics and Personalized Medicine 2016, 9:7-16

Published Date: 22 January 2016

Original Research

Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility

Saldivar JS, Taylor D, Sugarman EA, Cullors A, Garces JA, Oades K, Centeno J

Pharmacogenomics and Personalized Medicine 2016, 9:1-6

Published Date: 19 January 2016

Review

Variations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancer

Heeg S

Pharmacogenomics and Personalized Medicine 2015, 8:171-180

Published Date: 4 December 2015

Original Research

The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand

Bushyakanist A, Puangpetch A, Sukasem C, Kiertiburanakul S

Pharmacogenomics and Personalized Medicine 2015, 8:163-170

Published Date: 5 November 2015

Original Research

A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study

Damronglerd P, Sukasem C, Thipmontree W, Puangpetch A, Kiertiburanakul S

Pharmacogenomics and Personalized Medicine 2015, 8:155-162

Published Date: 3 October 2015

Review

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib

El-Osta H, Shackelford R

Pharmacogenomics and Personalized Medicine 2015, 8:145-154

Published Date: 29 September 2015

Original Research

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial

Balk JM, Haenen GRMM, Koc ÖM, Peters R, Bast A, van der Vijgh WJF, Koek GH

Pharmacogenomics and Personalized Medicine 2015, 8:137-144

Published Date: 12 August 2015

Review

Olaparib in the management of ovarian cancer

Bixel K, Hays JL

Pharmacogenomics and Personalized Medicine 2015, 8:127-135

Published Date: 7 August 2015

Review

Economic evaluations of personalized medicine: existing challenges and current developments

Shabaruddin FH, Fleeman ND, Payne K

Pharmacogenomics and Personalized Medicine 2015, 8:115-126

Published Date: 24 June 2015

Original Research

The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors

Sychev DA, Denisenko NP, Sizova ZM, Grachev AV, Velikolug KA

Pharmacogenomics and Personalized Medicine 2015, 8:111-114

Published Date: 27 May 2015

Review

The current and future state of companion diagnostics

Agarwal A, Ressler D, Snyder G

Pharmacogenomics and Personalized Medicine 2015, 8:99-110

Published Date: 31 March 2015

Original Research

Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics

Frick A, Fedoriw Y, Richards K, Damania B, Parks B, Suzuki O, Benton CS, Chan E, Thomas RS, Wiltshire T

Pharmacogenomics and Personalized Medicine 2015, 8:81-98

Published Date: 26 February 2015

Review

Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR

Richer AL, Friel JM, Carson VM, Inge LJ, Whitsett TG

Pharmacogenomics and Personalized Medicine 2015, 8:63-79

Published Date: 20 February 2015

Review

Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics

Beitelshees AL, Voora D, Lewis JP

Pharmacogenomics and Personalized Medicine 2015, 8:43-61

Published Date: 9 February 2015

Original Research

Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists

Obara T, Abe S, Satoh M, Gutiérrez Ubeda SR, Yoshimachi S, Goto T

Pharmacogenomics and Personalized Medicine 2015, 8:35-41

Published Date: 29 January 2015

Review

Targeted treatments for multiple myeloma: specific role of carfilzomib

Sugumar D, Keller J, Vij R

Pharmacogenomics and Personalized Medicine 2015, 8:23-33

Published Date: 20 January 2015

Review

Asthma pharmacogenetics and the development of genetic profiles for personalized medicine

Ortega VE, Meyers DA, Bleecker ER

Pharmacogenomics and Personalized Medicine 2015, 8:9-22

Published Date: 16 January 2015

Review

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

Smolej L

Pharmacogenomics and Personalized Medicine 2015, 8:1-7

Published Date: 22 December 2014

Review

Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics

Agarwal A, Soliman MK, Sepah YJ, Do DV, Nguyen QD

Pharmacogenomics and Personalized Medicine 2014, 7:399-409

Published Date: 12 December 2014

Review

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability

Kayali Z, Schmidt WN

Pharmacogenomics and Personalized Medicine 2014, 7:387-398

Published Date: 8 December 2014

Original Research

Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms

Pithukpakorn M, Tiwawanwong T, Lalerd Y, Assawamakin A, Premasathian N, Tasanarong A, Thongnoppakhun W, Vongwiwatana A

Pharmacogenomics and Personalized Medicine 2014, 7:379-385

Published Date: 5 December 2014

Review

Patient profiling in diabetes and role of canagliflozin

Amblee A

Pharmacogenomics and Personalized Medicine 2014, 7:367-377

Published Date: 18 November 2014

Review

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

Momtaz P, Postow MA

Pharmacogenomics and Personalized Medicine 2014, 7:357-365

Published Date: 15 November 2014

Review

Applications of pharmacogenetics in children with attention-deficit/hyperactivity disorder

Levy F

Pharmacogenomics and Personalized Medicine 2014, 7:349-356

Published Date: 6 November 2014

Review

Clinical utility of pharmacogenomics in the management of hepatitis C

Trinks J, Hulaniuk ML, Redal MA, Flichman D

Pharmacogenomics and Personalized Medicine 2014, 7:339-347

Published Date: 20 October 2014

Review

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine

Sadeghi S, Olevsky O, Hurvitz SA

Pharmacogenomics and Personalized Medicine 2014, 7:329-338

Published Date: 15 October 2014

Review

Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders

Chang FC, Fung VS

Pharmacogenomics and Personalized Medicine 2014, 7:317-328

Published Date: 13 October 2014

Review

Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition

Audeh MW

Pharmacogenomics and Personalized Medicine 2014, 7:307-316

Published Date: 3 October 2014

Original Research

Pharmacogenetic information for patients on drug labels

Haga SB, Mills R, Moaddeb J

Pharmacogenomics and Personalized Medicine 2014, 7:297-305

Published Date: 3 October 2014

Review

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer

Yap TA, Popat S

Pharmacogenomics and Personalized Medicine 2014, 7:285-295

Published Date: 19 September 2014

Review

Developing genomic knowledge bases and databases to support clinical management: current perspectives

Huser V, Sincan M, Cimino JJ

Pharmacogenomics and Personalized Medicine 2014, 7:275-283

Published Date: 9 September 2014

Review

Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling

Femminella GD, Barrese V, Ferrara N, Rengo G

Pharmacogenomics and Personalized Medicine 2014, 7:267-273

Published Date: 9 September 2014

Review

Developments in renal pharmacogenomics and applications in chronic kidney disease

Padullés A, Rama I, Llaudó I, Lloberas N

Pharmacogenomics and Personalized Medicine 2014, 7:251-266

Published Date: 28 August 2014

Review

Simeprevir for the treatment of hepatitis C virus infection

Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E

Pharmacogenomics and Personalized Medicine 2014, 7:241-249

Published Date: 14 August 2014

Review

Implementation and utilization of genetic testing in personalized medicine

Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA

Pharmacogenomics and Personalized Medicine 2014, 7:227-240

Published Date: 13 August 2014

Expert Opinion

Analytical strategies for discovery and replication of genetic effects in pharmacogenomic studies

Kohler JR, Guennel T, Marshall SL

Pharmacogenomics and Personalized Medicine 2014, 7:217-225

Published Date: 13 August 2014

Review

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways

Hosford SR, Miller TW

Pharmacogenomics and Personalized Medicine 2014, 7:203-215

Published Date: 6 August 2014

Review

Dysregulation of the homeobox transcription factor gene HOXB13: role in prostate cancer

Decker B, Ostrander EA

Pharmacogenomics and Personalized Medicine 2014, 7:193-201

Published Date: 5 August 2014

Review

MicroRNA binding site polymorphisms as biomarkers in cancer management and research

Cipollini M, Landi S, Gemignani F

Pharmacogenomics and Personalized Medicine 2014, 7:173-191

Published Date: 23 July 2014

Original Research

CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML

Pharmacogenomics and Personalized Medicine 2014, 7:163-171

Published Date: 14 July 2014

Original Research

Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties

Johansen Taber KA, Dickinson BD

Pharmacogenomics and Personalized Medicine 2014, 7:145-162

Published Date: 10 July 2014

Review

Targeting metastatic colorectal cancer – present and emerging treatment options

Ciombor KK, Berlin J

Pharmacogenomics and Personalized Medicine 2014, 7:137-144

Published Date: 8 July 2014

Review

Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach

Ceriello A, Gallo M, Candido R, De Micheli A, Esposito K, Gentile S, Medea G

Pharmacogenomics and Personalized Medicine 2014, 7:129-136

Published Date: 19 June 2014

Rapid Communication

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders

Saruwatari J, Nakashima H, Tsuchimine S, Nishimura M, Ogusu N, Yasui-Furukori N

Pharmacogenomics and Personalized Medicine 2014, 7:121-127

Published Date: 28 April 2014

Original Research

Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients

Caruso A, Bellia C, Pivetti A, Agnello L, Bazza F, Scazzone C, Bivona G, Lo Sasso B, Ciaccio M

Pharmacogenomics and Personalized Medicine 2014, 7:117-120

Published Date: 2 April 2014

Review

Targeted treatments in advanced renal cell carcinoma: focus on axitinib

Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, De Braud F, Procopio G

Pharmacogenomics and Personalized Medicine 2014, 7:107-116

Published Date: 27 March 2014

Review

Precision medicine and personalized breast cancer: combination pertuzumab therapy

Reynolds K, Sarangi S, Bardia A, Dizon DS

Pharmacogenomics and Personalized Medicine 2014, 7:95-105

Published Date: 20 March 2014

Review

ALK-driven tumors and targeted therapy: focus on crizotinib

Murga-Zamalloa C, Lim MS

Pharmacogenomics and Personalized Medicine 2014, 7:87-94

Published Date: 20 March 2014

Review

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma

Siddiqi T, Thomas SH, Chen R

Pharmacogenomics and Personalized Medicine 2014, 7:79-85

Published Date: 20 February 2014

Review

Glioblastoma extracellular vesicles: reservoirs of potential biomarkers

Redzic JS, Ung TH, Graner MW

Pharmacogenomics and Personalized Medicine 2014, 7:65-77

Published Date: 13 February 2014

Review

Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics

Noguchi K, Katayama K, Sugimoto Y

Pharmacogenomics and Personalized Medicine 2014, 7:53-64

Published Date: 5 February 2014

Review

Molecular variants and mutations in medulloblastoma

Schroeder K, Gururangan S

Pharmacogenomics and Personalized Medicine 2014, 7:43-51

Published Date: 4 February 2014

Review

Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide

Serpe L, Gallicchio M, Canaparo R, Dosio F

Pharmacogenomics and Personalized Medicine 2014, 7:31-42

Published Date: 29 January 2014

Review

Dabrafenib for treatment of BRAF-mutant melanoma

Kainthla R, Kim KB, Falchook GS

Pharmacogenomics and Personalized Medicine 2014, 7:21-29

Published Date: 31 December 2013

Review

Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients

Tessari A, Palmieri D, Di Cosimo S

Pharmacogenomics and Personalized Medicine 2014, 7:1-19

Published Date: 16 December 2013

Review

Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer

Leamon PC, Lovejoy CD, Nguyen B

Pharmacogenomics and Personalized Medicine 2013, 6:113-125

Published Date: 25 September 2013

Perspectives

Delivering pharmacogenetic testing in a primary care setting

Mills R, Voora D, Peyser B, Haga SB

Pharmacogenomics and Personalized Medicine 2013, 6:105-112

Published Date: 18 September 2013

Short Report

Lack of correlation between in silico projection of function and quantitative real-time PCR-determined gene expression levels in colon tissue

Penney RB, Lundgreen A, Yao-Borengasser A, Koroth-Edavana V, Williams S, Wolff R, Slattery ML, Kadlubar S

Pharmacogenomics and Personalized Medicine 2013, 6:99-103

Published Date: 9 September 2013

Original Research

Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen

Sensorn I, Sirachainan E, Chamnanphol M, Pasomsub E, Trachu N, Supavilai P, Sukasem C, Pinthong D

Pharmacogenomics and Personalized Medicine 2013, 6:93-98

Published Date: 26 August 2013

Original Research

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors

Sukasem C, Tunthong R, Chamnanphon M, Santon S, Jantararoungtong T, Koomdee N, Prommas S, Puangpetch A, Vathesatogkit P

Pharmacogenomics and Personalized Medicine 2013, 6:85-91

Published Date: 22 August 2013

Review

Role of biomarkers in understanding and treating children with asthma: towards personalized care

Lang JE, Blake KV

Pharmacogenomics and Personalized Medicine 2013, 6:73-84

Published Date: 21 August 2013

Original Research

ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro

Skoglund K, Boiso Moreno S, Baytar M, Jönsson JI, Gréen H

Pharmacogenomics and Personalized Medicine 2013, 6:63-72

Published Date: 20 August 2013

Review

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia

El Rassi F, Khoury HJ

Pharmacogenomics and Personalized Medicine 2013, 6:57-62

Published Date: 5 August 2013

Review

Molecular targeted therapies in metastatic melanoma

Chakraborty R, Wieland CN, Comfere NI

Pharmacogenomics and Personalized Medicine 2013, 6:49-56

Published Date: 7 June 2013

Original Research

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen

Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, Sensorn I, Sukasem C

Pharmacogenomics and Personalized Medicine 2013, 6:37-48

Published Date: 24 May 2013

Review

Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies

Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA

Pharmacogenomics and Personalized Medicine 2013, 6:25-36

Published Date: 4 April 2013

Original Research

Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects

Yu X, Kubota T, Dhakal I, Hasegawa S, Williams S, Ozawa S, Kadlubar S

Pharmacogenomics and Personalized Medicine 2013, 6:19-24

Published Date: 6 March 2013

Original Research

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer

Zhang X, Huang M, Wu X, Kadlubar S, Lin J, Yu X, Fan C, Ning B, Kadlubar FF

Pharmacogenomics and Personalized Medicine 2013, 6:9-17

Published Date: 1 March 2013

Case report

Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report

Tan-kam T, Suthisisang C, Pavasuthipaisit C, Limsila P, Puangpetch A, Sukasem C

Pharmacogenomics and Personalized Medicine 2013, 6:3-7

Published Date: 11 January 2013

Corrigendum

Pharmacogenomic considerations in opioid analgesia. [Corrigendum]

Vuilleumier PH, Stamer UM, Landau R

Pharmacogenomics and Personalized Medicine 2013, 6:1-2

Published Date: 14 January 2013

Original Research

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, Sukasem C

Pharmacogenomics and Personalized Medicine 2012, 5:149-153

Published Date: 17 October 2012

Review

Drug targets and predictive biomarkers in the management of metastatic melanoma

Thumar J, Giesen E, Kluger HM

Pharmacogenomics and Personalized Medicine 2012, 5:139-148

Published Date: 28 September 2012

Review

Boceprevir and personalized medicine in hepatitis C virus infection

Habersetzer F, Leboeuf C, Doffoël M, Baumert TF

Pharmacogenomics and Personalized Medicine 2012, 5:125-137

Published Date: 26 September 2012

Review

Personalized medicine and treatment approaches in non-small-cell lung carcinoma

Vadakara J, Borghaei H

Pharmacogenomics and Personalized Medicine 2012, 5:113-123

Published Date: 25 September 2012

Original Research

Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent

AL-Eitan LN, Jaradat SA, Su SY, Tay GK, Hulse GK

Pharmacogenomics and Personalized Medicine 2012, 5:99-111

Published Date: 7 September 2012

Review

Role of pharmacogenomics in the treatment of tuberculosis: a review

Ramachandran G, Swaminathan S

Pharmacogenomics and Personalized Medicine 2012, 5:89-98

Published Date: 13 September 2012

Review

Pharmacogenomic considerations in opioid analgesia

Vuilleumier PH, Stamer UM, Landau R

Pharmacogenomics and Personalized Medicine 2012, 5:73-87

Published Date: 23 August 2012

Review

Individualized immunosuppression in transplant patients: potential role of pharmacogenetics

Abboudi H, MacPhee IA

Pharmacogenomics and Personalized Medicine 2012, 5:63-72

Published Date: 18 June 2012

Original Research

ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics

Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJR, Somogyi AA

Pharmacogenomics and Personalized Medicine 2012, 5:53-62

Published Date: 18 April 2012

Review

The role of genetics in pre-eclampsia and potential pharmacogenomic interventions

Williams PJ, Morgan L

Pharmacogenomics and Personalized Medicine 2012, 5:37-51

Published Date: 20 January 2012

Review

Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy

Kenna GA, Roder-Hanna N, Leggio L, Zywiak WH, Clifford J, Edwards S, Kenna JA, Shoaff J, Swift RM

Pharmacogenomics and Personalized Medicine 2012, 5:19-35

Published Date: 13 January 2012

Review

Individualization of antiretroviral therapy

Pavlos R, Phillips EJ

Pharmacogenomics and Personalized Medicine 2012, 5:1-17

Published Date: 29 December 2011

Original Research

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S

Pharmacogenomics and Personalized Medicine 2011, 4:137-145

Published Date: 17 November 2011

Review

Role of cytochrome P450 genotype in the steps toward personalized drug therapy

Cavallari LH, Jeong H, Bress A

Pharmacogenomics and Personalized Medicine 2011, 4:123-136

Published Date: 7 November 2011

Review

Clinical application of high throughput molecular screening techniques for pharmacogenomics

Wiita AP, Schrijver I

Pharmacogenomics and Personalized Medicine 2011, 4:109-121

Published Date: 8 September 2011

Review

Clinical implementation of RNA signatures for pharmacogenomic decision-making

Tang W, Hu Z, Muallem H, Gulley ML

Pharmacogenomics and Personalized Medicine 2011, 4:95-107

Published Date: 8 September 2011

Review

Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gain

Wallace TJM, Zai CC, Brandl EJ, Müller DJ

Pharmacogenomics and Personalized Medicine 2011, 4:83-93

Published Date: 18 August 2011

Review

Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family

Lucire Y, Crotty C

Pharmacogenomics and Personalized Medicine 2011, 4:65-81

Published Date: 1 August 2011

Review

ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer

Vaezi A, Feldman CH, Niedernhofer LJ

Pharmacogenomics and Personalized Medicine 2011, 4:47-63

Published Date: 20 July 2011

Original Research

A genetic approach to the prediction of drug side effects: bleomycin induces concordant phenotypes in mice of the collaborative cross

Gelinas R, Chesler EJ, Vasconcelos D, Miller DR, Yuan Y, Wang K, Galas D

Pharmacogenomics and Personalized Medicine 2011, 4:35-45

Published Date: 4 July 2011

Review

Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy

Bluth MH, Li J

Pharmacogenomics and Personalized Medicine 2011, 4:11-33

Published Date: 1 April 2011

Review

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer

Pietro Carotenuto, Cristin Roma, Anna Maria Rachiglio, et al

Pharmacogenomics and Personalized Medicine 2011, 4:1-9

Published Date: 14 March 2011

Review

The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes

Veronica Lang, Peter E Light

Pharmacogenomics and Personalized Medicine 2010, 3:145-161

Published Date: 24 November 2010

Review

Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management

Sarah Rofaiel, Esther N Muo, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2010, 3:129-143

Published Date: 17 September 2010

Review

The future role of personalized medicine in the treatment of glioblastoma multiforme

Jing Li, Chunhui Di, Austin K Mattox, et al

Pharmacogenomics and Personalized Medicine 2010, 3:111-127

Published Date: 19 August 2010

Review

Antiplatelet agents and proton pump inhibitors – personalizing treatment

Eugene Lin, Rajiv Padmanabhan, Majaz Moonis

Pharmacogenomics and Personalized Medicine 2010, 3:101-109

Published Date: 28 June 2010

Review

Impact of genetic polymorphisms on clinical response to antithrombotics

Kena J Lanham, Julie H Oestreich, Steven P Dunn, et al

Pharmacogenomics and Personalized Medicine 2010, 3:87-99

Published Date: 18 June 2010

Review

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab

Naveed Wagle, Leia Nghiemphu, Albert Lai, et al

Pharmacogenomics and Personalized Medicine 2010, 3:79-85

Published Date: 9 June 2010

Review

DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics

Darko Turic, James Swanson, Edmund Sonuga-Barke

Pharmacogenomics and Personalized Medicine 2010, 3:61-78

Published Date: 21 May 2010

Review

Ofatumumab: a novel monoclonal anti-CD20 antibody

Thomas S Lin

Pharmacogenomics and Personalized Medicine 2010, 3:51-59

Published Date: 10 May 2010

Review

Determinants to optimize response to clopidogrel in acute coronary syndrome

Betti Giusti, Anna Maria Gori, Rossella Marcucci, et al

Pharmacogenomics and Personalized Medicine 2010, 3:33-50

Published Date: 8 April 2010

Review

Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies

Darren D O’Rielly, Proton Rahman

Pharmacogenomics and Personalized Medicine 2010, 3:15-31

Published Date: 30 March 2010

Review

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin

Roberto J Carvalho-Filho, Olav Dalgard

Pharmacogenomics and Personalized Medicine 2010, 3:1-13

Published Date: 11 March 2010

Review

The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent

Hector Clarke, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:93-99

Published Date: 10 September 2009

Review

Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine

Peter Avery, Shaymaa S Mousa, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:79-91

Published Date: 13 September 2009

Review

Pharmacogenomics in osteoporosis: Steps toward personalized medicine

Robert Greene, Shaymaa S Mousa, Mohamed Ardawi, et al

Pharmacogenomics and Personalized Medicine 2009, 2:69-78

Published Date: 10 September 2009

Review

Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine

Christopher Barone, Shaymaa S Mousa, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:59-67

Published Date: 8 September 2009

Original Research

Influence of socioeconomic lifestyle factors and genetic polymorphism on type 2 diabetes occurrences among Tunisian Arab and Berber groups of Djerba Island

Thouraya Baroudi Ouederni, Ahmed Fadiel, Nejla Stambouli, et al

Pharmacogenomics and Personalized Medicine 2009, 2:49-57

Published Date: 21 August 2009

Review

Genomics and proteomics: Applications in autoimmune diseases

Wolfgang Hueber, William H Robinson

Pharmacogenomics and Personalized Medicine 2009, 2:39-48

Published Date: 17 August 2009

Review

Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed

Steven F Powell, Arkadiusz Z Dudek

Pharmacogenomics and Personalized Medicine 2009, 2:21-37

Published Date: 24 June 2009

Original Research

Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis

Janet K Coller, Julia Beardsley, James Bignold, Yibai Li, Florence Merg, et al

Pharmacogenomics and Personalized Medicine 2009, 2:9-19

Published Date: 20 March 2009

Review

Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction

Avery Schwartz, Shany Blum, Rabea Asleh, Mordechai Pollak, Shiri Kalet-Litman, Andrew P Levy

Pharmacogenomics and Personalized Medicine 2009, 2:1-8

Published Date: 27 February 2009

Perspectives

Integrating epigenomics into pharmacogenomic studies

Wei Zhang, R Stephanie Huang, M Eileen Dolan

Pharmacogenomics and Personalized Medicine 2008, 1:7-14

Published Date: 2 November 2008

Original Research

Association study of a brain-derived neurotrophic factor polymorphism and short-term antidepressant response in major depressive disorders

Eugene Lin, Po See Chen, Lung-Cheng Huang, Sen-Yen Hsu

Pharmacogenomics and Personalized Medicine 2008, 1:1-6

Published Date: 21 October 2008